Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Suite 140
Newark
California
94560
United States
Tel: 650-587-5766
Fax: n./a
Website: http://www.protagonist-inc.com/
Email: info@protagonist-inc.com
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, lower cost, and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn's disease.
YEAR FOUNDED:
2001
LEADERSHIP:
Founder: Mark Symythe
CEO: Dinesh Patel
CMO (Marketing): Richard Shames
CFO: Tom O’Neil
CSO (Scientific): David Liu
JOBS:
Please click here for Protagonist Therapeutics job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
233 articles about Protagonist Therapeutics, Inc.
-
Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
11/7/2017
Protagonist Therapeutics today reported its financial results for the third quarter and nine months ended September 30, 2017 and provided an update on the company's recent achievements.
-
Protagonist Announces Proposed Public Offering Of Common Stock
10/12/2017
-
Protagonist Announces Preliminary Phase I Study Results With Novel Hepcidin Mimetic, PTG-300
9/20/2017
-
Protagonist Announces Closing Of Janssen Pharmaceutical License And Collaboration Agreement For PTG-200 And Receipt Of $50 Million Payment
8/25/2017
-
Protagonist Reports Second Quarter 2017 Financial Results And Business Highlights
8/9/2017
-
Protagonist Appoints Five Prime CEO, Lewis T. "Rusty" Williams, To Its Board Of Directors
6/8/2017
-
Can Protagonist Stock Still Double After Its Huge Gain?
5/31/2017
-
Protagonist Initiates Phase l Study with Novel Hepcidin Mimetic, PTG-300
5/25/2017
-
Protagonist Receives $1.34 Million SBIR Funding For Development Of Biomarkers Of IL-23 Receptor Antagonist Activity
5/24/2017
-
Protagonist Reports First Quarter 2017 Financial Results
5/11/2017
-
Key Patent Issues Covering Protagonist' Oral Peptide IL-23 Receptor Antagonists, Including The Development Candidate PTG-200
5/5/2017
-
Protagonist Reports Fourth Quarter And Year-End 2016 Financial Results
3/8/2017
-
Protagonist Presents Data On Oral Peptide Drug Candidates At European Crohn's And Colitis Organization (ECCO) Congress
2/17/2017
-
Protagonist Release: Pharma Initiates Phase 2b Study Of Oral Drug Candidate PTG-100 In Ulcerative Colitis
1/17/2017
-
Key Patent Is Issued Covering Protagonist' Alpha4Beta7 Integrin Peptide Inhibitors Including Oral Drug Candidate PTG-100
1/5/2017
-
Protagonist Reports Third Quarter 2016 Financial Results And Provides Corporate Update
11/15/2016
-
Bay Area's Protagonist Raises $90 Million in Upsized IPO
8/11/2016
-
Protagonist Therapeutics, a GI Biotech, Sets Terms for $70 Million IPO
8/1/2016
-
Protagonist Therapeutics Receives SBIR Funding For The Development Of Injectable Hepcidin Mimetics For Treatment Of Iron Overload Disorders
7/28/2016
-
William D. Waddill, Calithera Biosciences, Inc. CFO, Elected To Protagonist Therapeutics Board
7/8/2016